stockportfolio.pro
BMRN vs CRL: Which Stock Is the Better Buy?
BioMarin Pharmaceutical Inc. and Charles River Laboratories International, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BMRN vs CRL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| BioMarin Pharmaceutical Inc. (BMRN) | Charles River Laboratories International, Inc. (CRL) | |
|---|---|---|
| Market cap | $10.9B | $11.1B |
| Revenue (latest FY) | $3.22B | $4.02B |
| Net income (latest FY) | $348.90M | $-144.34M |
| Revenue growth (5y CAGR) | 11.6% | 6.5% |
| Net margin | 10.8% | -3.6% |
| Return on equity | 5.7% | -4.6% |
| P/E ratio | 40.4 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 9 |
| Positive free cash flow | Yes | Yes |
See the full BMRN vs CRL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BMRN's full financials → Open CRL's full financials →More comparisons
Frequently asked questions
Which is bigger, BMRN or CRL?
Charles River Laboratories International, Inc. is larger by market capitalization — $11.1B versus $10.9B.
Which grows faster, BMRN or CRL?
Over the last five fiscal years, BioMarin Pharmaceutical Inc. grew revenue faster — 11.6%/yr versus 6.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.